Skip to main content

Table 3 The effect of pregnancy and labor on MS outcomes

From: Outcomes of pregnancy in Egyptian women with multiple sclerosis in the new treatment era: a multi-center retrospective observational study

Characteristic

Total, n = 116

Pregnancy

 

 Relapse during pregnancy, no. (%)

13 (11.21%)

DMT use during pregnancya, no. (%)

 

 Intentionally

6 (5.17%)

 Accidentally (at first trimester)

38 (32.76%)

DMT type used (Intentionally)

 

 Interferon-beta

5 (83.33%)

DMT type used (Accidentally)

 

 Interferon-beta

15 (39.47%)

 Dimethyl fumarate

7 (18.42%)

 Fingolimod

12 (31.58%)

 Rituximab

3 (7.89%)

 ocrelizumab

1 (2.63%)

Postpartum period

 

 No. of pregnancies with postpartum relapses, no. (%)

 

  0

85 (73.28%)

  1

24 (20.69%)

  2

5 (4.31%)

  ≥ 3

2 (1.72%)

Time to first postpartum relapseb, median (IQR), days

171 (78–232)

DMT use during postpartum year, no. (%)

 

 None

69 (59.48%)

 Interferon-beta

22 (18.97%)

 Dimethyl fumarate

7 (6.03%)

 Natalizumab

3 (2.57%)

 Rituximab

4 (3.45)

 Fingolimod

8 (6.90%)

 Ocrelizumab

3 (2.57%)

 Time to restart DMT after deliveryc (median, IQR), d

86 (29–201)

  1. DMT disease-modifying therapy; IQR interquartile range; MS multiple sclerosis
  2. aDuring the second and/or third trimester
  3. bOf those who relapse
  4. cOf those who resumed DMTs